Extracellular Vesicle Therapy for Type 1 Diabetes

Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular ve...

Descripción completa

Detalles Bibliográficos
Autores principales: Soltani, Setareh, Mansouri, Kamran, Emami Aleagha, Mohammad Sajad, Moasefi, Narges, Yavari, Niloofar, Shakouri, Seyed Kazem, Notararigo, Sara, Shojaeian, Ali, Pociot, Flemming, Yarani, Reza
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024141/
https://www.ncbi.nlm.nih.gov/pubmed/35464488
http://dx.doi.org/10.3389/fimmu.2022.865782
Descripción
Sumario:Type 1 diabetes (T1D) is a chronic disorder characterized by immune-mediated destruction of pancreatic insulin-producing β-cells. The primary treatment for T1D is multiple daily insulin injections to control blood sugar levels. Cell-free delivery packets with therapeutic properties, extracellular vesicles (EVs), mainly from stem cells, have recently gained considerable attention for disease treatments. EVs provide a great potential to treat T1D ascribed to their regenerative, anti-inflammatory, and immunomodulatory effects. Here, we summarize the latest EV applications for T1D treatment and highlight opportunities for further investigation.

Ejemplares similares